Bayer Oncology

Patient Support Services Guide 2018


Oncology $0 Co-Pay Program
866-639-2827
Xofigo Access Services
855-696-3446

Bayer HealthCare offers comprehensive support services for eligible patients who are prescribed their Bayer oncology drugs through several patient support programs, including its Oncology $0 Co-Pay Program, the REACH (Resources for Expert Assistance and Care Helpline) program, the Xofigo Access Services program, and the Aliqopa Resource Connections program.

The list of oncology medicines covered by Bayer Oncology support services is provided in the Table.

Bayer Oncology Support Programs

Oncology $0 Co-Pay Program

Through the REACH program, eligible patients with private insurance can have a $0 copay for Stivarga (regorafenib) or for Nexavar (sorafenib), and up to $25,000 annually per patient.

Aliqopa Resource Connections

Patients with private insurance may be eligible for copay assistance for Aliqopa (copanlisib) through the Aliqopa $0 Co-Pay Program, which covers out-of-pocket expenses for Aliqopa for up to $25,000 annually.

The Aliqopa Resource Connections Patient Assistance Program provides Aliqopa free of charge to eligible patients who are uninsured or underinsured. For more information on Aliqopa Resource Connections, visit this website or call 833-254-7672.

The REACH Program

The REACH program provides financial assistance services for patients who are prescribed Stivarga or Nexavar and have no insurance, are underinsured, or have Medicare coverage. The REACH program also offers referrals to third-party nonprofit foundations for assistance with out-of-pocket expenses.

To find out more about the REACH reimbursement and support services, call their hotline at 866-639-2827 or visit ReachPatientSupport.com.

Xofigo Access Services

Xofigo Access Services is designed to provide dedicated support services for Xofigo (radium Ra 223 dichloride). Patients with private insurance may be eligible for copay assistance for Xofigo through Xofigo Commercial Copay Assistance. The Xofigo Patient Assistance Program provides Xofigo free of charge to eligible patients who are uninsured or lack coverage for Xofigo. For more information on Xofigo Access Services, visit this website or call 855-696-3446.

Eligibility

Oncology $0 Co-Pay Program

To be eligible for the Oncology $0 Co-Pay Program for Stivarga or Nexavar, patients must:

  • Be a US resident
  • Be aged ≥18 years
  • Use Stivarga or Nexavar for an FDA-approved indication
  • Have commercial insurance for a portion of prescription drug cost
  • Not be enrolled in Medicare, Medicaid, or any government-­funded programs
  • Not seek reimbursement from any third-party payer, such as a flexible spending account, a healthcare savings account, or a health reimbursement account
  • Not have previously been enrolled in the REACH Commercial Co-Pay Assistance Program.

Patient eligibility will be reassessed annually. Patients will be assessed for temporary patient assistance, if prior authorization determinations are delayed or denied.

Aliqopa $0 Co-Pay Program

To be eligible for the Aliqopa $0 Co-Pay Program, patients must:

  • Reside in the United States
  • Have commercial insurance
  • Have a valid prescription for Aliqopa
  • Not have their prescription for Aliqopa covered by Medicare (including Part D), Medicaid, or similar federal- or state-funded programs.

Income documentation is not required for patients with commercial insurance who are applying for copay assistance.

Aliqopa Resource Connections Patient Assistance Program

Patients receiving Aliqopa may be eligible to enroll in the Aliqopa Resource Connections Patient Assistance Program if they have no insurance or are underinsured. Income documentation is required for eligibility assessment, and acceptable forms of documentation include the most recent US federal tax return, Social Security income statements, and recent pay stubs. Information about the Aliqopa Resource Connections Patient Assistance Program can be viewed here.

REACH Patient Assistance Program

Patients receiving Stivarga or Nexavar may be eligible to enroll in the REACH Patient Assistance Program if they have no insurance, are underinsured, or have Medicare or Medicaid. Eligibility information about patient assistance programs can be found at ReachPatientSupport.com, or by calling 866-639-2827. Patients must meet the financial criteria with proof of income.

Xofigo Patient Assistance Program

To be eligible for the Xofigo Patient Assistance Program, patients must:

  • Be uninsured or lack coverage for Xofigo
  • Reside in the United States
  • Receive treatment in a physician’s office or an outpatient hospital
  • Meet financial criteria based on adjusted gross household income (documentation of income is required).

Xofigo Commercial Copay Assistance

To be eligible for the Xofigo Commercial Copay Assistance program, patients must:

  • Be privately insured
  • Reside in the United States, including the District of Columbia, Puerto Rico, Guam, or the US Virgin Islands
  • Receive treatment in a physician’s office or an outpatient hospital
  • Not be enrolled in the Bayer Patient Assistance Program or Xofigo Access Services
  • Not be enrolled in Medicare, Medicaid, or any government-funded programs.

This program covers 100% of a patient’s copay. For qualified publicly insured patients, the program also offers referrals to independent copay assistance foundations.

Application & Enrollment

Oncology $0 Co-Pay Program

Enrollment for the $0 Co-Pay Program is a 3-step process, with no forms, faxes, or signatures required. The $0 Co-Pay Program can be accessed for Nexavar and for Stivarga, or by calling 866-581-4992.

Patients who are currently enrolled in the income-based tiered program will remain in that program until their annual enrollment expires. When their annual enrollment expires, these patients will be eligible for the $0 Co-Pay Program. Enrollment in the $0 Co-Pay Program is valid for 3 years. The maximum annual benefit is $25,000.

Aliqopa $0 Co-Pay Program

To enroll in the Aliqopa $0 Co-Pay Program, patients and their providers must fill out the Aliqopa $0 Co-Pay Program Reimbursement Form. Completed forms, along with a dated pharmacy receipt indicating Aliqopa payment or Explanation of Benefits, and (if reimbursement is requested to be issued directly to the patient) proof of copay/coinsurance payment, should be submitted by fax to 833-252-6729, or by mail to the address on the form. Reimbursement claims must be submitted within 180 days of the date of service.

Aliqopa Resource Connections Patient Assistance Program

To enroll in this program, the patient or provider can fax a completed Aliqopa Resource Connections Patient Assistance Program Enrollment Form to 833-427-2329, or mail it to the PO Box listed on the form. The enrollment form is available online.

Aliqopa Resource Connections will reach out to the patient regarding the outcome of their enrollment.

The REACH Program

Applications for the REACH program can be downloaded from ReachPatientSupport.com or obtained by calling 866-639-2827. All 3 completed forms (physician, patient information, and patient authorization) must be faxed to 866-639-5181.

Xofigo Access Services

Application for the Xofigo Access Services program must be completed by the physician, including the signed Patient Authorization form, and faxed to 855-963-4463. The preferred service for patients may also be requested using the Xofigo Access Services Provider Portal. Income documentation is required for the Xofigo Patient Assistance Program (include the most recent copy of US federal tax return, Social Security income statements, recent pay stubs). If applying for Xofigo Commercial Copay Assistance, a signed Assignment of Commercial Copay and Coinsurance Assistance must be completed.

The physician directly receives the Xofigo copay/coinsurance assistance funds; the patient receives a Commercial Copay Assistance identification card, which should be presented to the physician along with the insurance information.

Additional Services

The Nursing Support Services of the REACH program provide a comprehensive list of services for patients and providers, including:

  • Benefit verification/prior authorizations and appeals information
  • Specialty pharmacy provider identification
  • Alternate coverage research for the uninsured and underinsured
  • Information on Medicare Part D plan
  • Medicaid application and enrollment
  • Access to REACH nurse counselors for education and support relating to adverse event management and refill reminders
  • Periodic outreach calls from REACH nurse counselors.

Additional support services that are provided by the Xofigo Access Services include:

  • Product ordering
  • Confirming patient appointment and treatment schedules
  • Reimbursement support, including insurance benefit verification, prior authorization support, claims appeal research and tracking, payer policy information, and billing and coding information.

Table Bayer Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Aliqopa (copanlisib) for injection
Indication
Relapsed follicular lymphoma in adults after ≥2 systemic therapies
Patient support program

Drug
Nexavar (sorafenib)
Indication
Unresectable hepatocellular carcinoma; advanced renal-cell carcinoma; locally recurrent or metastatic, progressive, differentiated thyroid carcinoma

Drug
Stivarga (regorafenib)
Indication
Metastatic colorectal cancer; unresectable or metastatic gastrointestinal stromal tumors; hepatocellular carcinoma

Drug
Xofigo (radium Ra 223 dichloride) injection
Indication
Metastatic, castration-resistant prostate cancer
Patient support program